Bill Ponton, Chief Executive Officer
Bill Ponton has more than 15 years of experience leading successful venture-backed technology and biotech startups including: Vivid Technology, Vertasent, AnySource Media, CDI Bioscience and Targeted Therapeutics. Prior to his work with startups, Bill was a member of the staff of Princeton University in the Plasma Physics Lab. He holds an MBA from NYU Stern School of Business and a BSEE from Rutgers University College of Engineering.
Victor Levenson, MD, PhD, Chief Science Officer
Dr. Victor Levenson has more than 20 years of experience directing research and development for genetic and epigenetic discovery, with a strong focus on molecular diagnostics.
Dr. Levenson is co-Founder of CDI Bioscience, Inc. a company providing products and services that enhance biopharmaceutical production and co-Founder and CSO of Targeted Therapeutics, LLC. a preclinical biopharmaceutical company developing novel therapeutics that target cancer cells by disrupting multiple signaling pathways that cancer cells depend on for survival.
Dr. Levenson received his MD from the Pirogov’s Second Moscow State Medical Institute in Moscow, USSR and PhD from the Institute of Molecular Biology in Moscow, USSR in the field of Molecular and Cellular Biology. Dr. Levenson has held faculty positions at the Institute of Molecular Biology (Moscow, USSR) in Molecular and Cellular Biology, University of Illinois at Chicago, Northwestern University, and Rush University Medical Center.
Dr. Levenson has received numerous awards, including two American Cancer Society Young Investigator awards, a National Institutes of Health FIRST Award, and three Susan G. Komen For the Cure awards for research into methylation patterns of breast cancer genes. Dr. Levenson was the Principal Investigator on multiple grants, has published more than three dozen peer-reviewed articles, reviews, and book chapters, and gave numerous invited presentations at different scientific meetings. Victor is the author of five issued patents and three ongoing patent applications, mainly in the field of blood-based biomarkers.